Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

ESMO Guidelines Committee

doi:10.1016/j.annonc.2022.10.001

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ^☆

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

384 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1217-1238
Nombre de pages	22
journal	Annals of Oncology
Volume	33
Numéro de publication	12
Les DOIs	https://doi.org/10.1016/j.annonc.2022.10.001
état	Publié - 1 déc. 2022

Accès au document

10.1016/j.annonc.2022.10.001

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{3f1c7d6127ec4191846d711f66650bd9,

title = "Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆",

keywords = "ESMO Clinical Practice Guideline, immunotherapy, side-effects, toxicity, treatment",

author = "{ESMO Guidelines Committee} and J. Haanen and M. Obeid and L. Spain and F. Carbonnel and Y. Wang and C. Robert and Lyon, {A. R.} and W. Wick and M. Kostine and S. Peters and K. Jordan and J. Larkin",

note = "Funding Information: ARL is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology . Manuscript editing support was provided by Ioanna Ntai and Catherine Evans (ESMO Guidelines staff) and Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO . ",

year = "2022",

month = dec,

day = "1",

doi = "10.1016/j.annonc.2022.10.001",

language = "English",

volume = "33",

pages = "1217--1238",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "12",

}

TY - JOUR

T1 - Management of toxicities from immunotherapy

T2 - ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

AU - ESMO Guidelines Committee

AU - Haanen, J.

AU - Obeid, M.

AU - Spain, L.

AU - Carbonnel, F.

AU - Wang, Y.

AU - Robert, C.

AU - Lyon, A. R.

AU - Wick, W.

AU - Kostine, M.

AU - Peters, S.

AU - Jordan, K.

AU - Larkin, J.

N1 - Funding Information: ARL is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology . Manuscript editing support was provided by Ioanna Ntai and Catherine Evans (ESMO Guidelines staff) and Angela Corstorphine of Kstorfin Medical Communications Ltd; this support was funded by ESMO .

PY - 2022/12/1

Y1 - 2022/12/1

KW - ESMO Clinical Practice Guideline

KW - immunotherapy

KW - side-effects

KW - toxicity

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85141947187&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2022.10.001

DO - 10.1016/j.annonc.2022.10.001

M3 - Article

C2 - 36270461

AN - SCOPUS:85141947187

SN - 0923-7534

VL - 33

SP - 1217

EP - 1238

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -